1. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
- Author
-
Lablanche S, Delagenière J, Jalbert M, Sonnet E, Benichou M, Arnold N, Spiteri A, Le Berre JP, Renard E, Chevalier N, Borot S, Bonnemaison E, Coffin C, Teissier MP, Benhamou PY, Borel JC, Penfornis A, Joubert M, and Kessler L
- Subjects
- Humans, Retrospective Studies, Male, Female, France, Adult, Middle Aged, Glycated Hemoglobin analysis, Treatment Outcome, Hypoglycemia prevention & control, Hypoglycemia chemically induced, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 blood, Insulin Infusion Systems, Blood Glucose analysis, Hypoglycemic Agents therapeutic use, Hypoglycemic Agents administration & dosage, Glycemic Control methods, Insulin administration & dosage, Insulin therapeutic use, Blood Glucose Self-Monitoring
- Abstract
Aim: To evaluate the evolution of glycemic outcomes in patients living with type 1 diabetes (T1D) after 1 year of use of the MiniMed 780G advanced hybrid closed-loop (AHCL) system. Methods: We conducted an observational, retrospective, multicentric study in 20 centers in France. The primary objective was to evaluate the improvement in glycemic control after 1-year use of AHCL. The primary endpoint was the variation of time in range (TIR) between pre-AHCL and after 1-year use of AHCL. Secondary objectives were to analyze the glycemic outcomes after 3, 6, and 12 months of AHCL use, the safety, and the long-term observance of AHCL. Results: Two hundred twenty patients were included, and 200 were analyzed for the primary endpoint. 92.7% of patients continued to use AHCL. After 1 year of use of AHCL, TIR was 72.5% ± 10.6% (+9.1%; 95% confidence interval [CI] [7.6-10.5] compared to pre-AHCL initiation, P < 0.001), HbA1c 7.1% ± 0.7% (-0.5%; 95% CI [-0.6 to -0.4]; P < 0.001), time below range 2.0% [1.0; 3.0] (0.0% [-2.0; 0.0], P < 0.001), and time above range 24.8% ± 10.9% (-7.3%; 95% CI [-8.8 to -5.7]; P < 0.001). More patients achieved the glycemic treatment goals of HbA1c <7.0% (45.1% vs. 18.1%, P < 0.001) and TIR >70% (59.0% vs. 29.5% P < 0.001) when compared with pre-AHCL. Five patients experienced severe hypoglycemia events and two patients experienced ketoacidosis. Conclusion: After 1 year of use of AHCL, people living with T1D safely improved their glucose control and a higher proportion of them achieved optimal glycemic control.
- Published
- 2024
- Full Text
- View/download PDF